Latest Regulatory News

Greatland Resources reports strong FY25 results with gold and copper production meeting guidance and costs significantly below expectations. The company advances Havieron feasibility and outlines ambitious FY26 growth capital plans to extend mine life and boost production.

Osteopore Limited reports a three-fold increase in craniofacial implant sales within a year of signing an exclusive distribution deal with Zimmer Biomet, signaling strong early traction across key global markets.

Change Financial Limited reported a record Q4 FY25 revenue of US$4.0 million, marking a 26% year-on-year increase, alongside positive underlying EBITDA and a strong outlook for FY26.

Osmond Resources has confirmed the award of the Orión Investigation Permit in Spain and is set to begin an initial drilling program this quarter, advancing its EU Critical Minerals Project amid strong regulatory support.

Greatland Resources has completed a landmark FY25, integrating Telfer and Havieron operations, producing nearly 200,000 ounces of gold, and raising $490 million in a successful ASX IPO. The company sets ambitious FY26 targets focused on extending Telfer’s mine life through its largest drilling program ever.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 amid promising regulatory and market developments.

EDU Holdings reports a modest 2% increase in total student enrolments for its Australian Learning Group in Term 3, 2025, while new student enrolments have sharply declined amid ongoing regulatory challenges.

Terramin Australia reports steady progress across multiple projects including key drilling at Tala Hamza and regulatory approvals at Kapunda, while navigating legal challenges at Bird in Hand. Algeria’s recent mining reforms offer a promising backdrop for the company’s expansion plans.

New World Resources has upgraded its Antler Copper Deposit resource to 14.2 million tonnes at 3.8% copper equivalent, secured key permitting milestones, and recommended shareholders accept a $0.067 per share takeover offer from Kinterra Capital.

LTR Pharma has initiated commercial distribution of its nasal spray SPONTAN through Australia's Symbion pharmacy network and is advancing ROXUS development for a US launch in early 2026, while expanding its pipeline with a new intranasal treatment for swallowing disorders.

EMVision Medical Devices has secured ethics approvals for two pivotal clinical studies and received a $400,000 milestone payment, marking significant progress toward commercialising its portable First Responder brain scanner.

Wildcat Resources has completed a positive Preliminary Feasibility Study for its Tabba Tabba lithium project in Western Australia, confirming a long-life mine with strong financial metrics and a clear path to development.